Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07639580
Enrolling by invitation Observational

Urinary Incontinence and Low Energy Avaliability in Professional and Pre-professional Dancers: a Cross-sectional Study

NCT07639580 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Siena
Phase
Observational
Started
2026-03-01
Last updated
2026-06-10

Condition(s) studied

Urinary IncontinenceRED-S

Investigational drug(s) / intervention(s)

ICIQ-UI-SF (International Consultation on Incontinence Questionnarie - Urinary Incontinence Short Form)

ICIQ-UI-SF (International Consultation on Incontinence Questionnarie - Urinary Incontinence Short Form): Participants will be administered 2 patient-reported outcome questionnaires

Study summary

The purpose of this study is to describe the prevalence of Urinary Incontinence amongst professional and pre-professional dancers and its relation to Low Energy Avaliability

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Professional dancers (must have danced professionally, with a work contract in the last 6 months) OR pre-professional student (currently enrolled in a high-level dance academy or pre-professional course) Exclusion Criteria: * Current or previous pregnancy * Low level of Italian or English language

Primary outcome measure(s)

  • Urinary Incontinence — 12 months
    Prevalence of Urinary Incontinence

Trial sites (1)

FacilityCityRegionStatus
University of Siena Siena Italy

More University of Siena trials in Italy

Full Mouth Ultrasonic Debridement Carried Out With Either Piezoelectric or Magnetostrictive Device Recruiting
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer Recruiting
Restoring Cervical Lymphatic Drainage in Alzheimer's Disease Recruiting
Loop Diuretic Therapy in Acutely Decompensated Heart Failure Recruiting
AutoInflammatory Disease Alliance Registry (AIDA) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07639580 on ClinicalTrials.gov ↗ ← All trials in Italy